共 58 条
Circulating Cystatin C Is an Independent Risk Marker for Cardiovascular Outcomes, Development of Renal Impairment, and Long-Term Mortality in Patients With Stable Coronary Heart Disease: The LIPID Study
被引:24
作者:
West, Malcolm
[1
]
Kirby, Adrienne
[2
]
Stewart, Ralph A.
[3
]
Blankenberg, Stefan
[4
]
Sullivan, David
[5
]
White, Harvey D.
[3
]
Hunt, David
[6
]
Marschner, Ian
[2
]
Janus, Edward
[7
]
Kritharides, Leonard
[8
,9
]
Watts, Gerald F.
[10
]
Simes, John
[2
]
Tonkin, Andrew M.
[11
]
机构:
[1] Univ Queensland, Dept Med, Brisbane, Qld, Australia
[2] Univ Sydney, Natl Hlth & Med Res Council Clin Trials Ctr, Sydney, NSW, Australia
[3] Univ Auckland, Auckland City Hosp, Green Lane Cardiovasc Serv, Auckland, New Zealand
[4] Univ Heart & Vasc Ctr Hamburg, Hamburg, Germany
[5] Royal Prince Alfred Hosp, Dept Chem Pathol, Sydney, NSW, Australia
[6] Royal Melbourne Hosp, Cardiol Dept, Melbourne, Vic, Australia
[7] Univ Melbourne, Melbourne Med Sch, Western Hlth, Dept Med,Western Hlth Chron Dis Alliance, Melbourne, Vic, Australia
[8] Sydney Local Hlth Dist, Concord Repatriat Gen Hosp, Dept Cardiol, Sydney, NSW, Australia
[9] Univ Sydney, Fac Med, ANZAC Med Res Inst, Sydney, NSW, Australia
[10] Univ Western Australia, Fac Hlth & Med Sci, Sch Med, Perth, WA, Australia
[11] Monash Univ, Sch Publ Hlth & Prevent Med, Perth, WA, Australia
来源:
JOURNAL OF THE AMERICAN HEART ASSOCIATION
|
2022年
/
11卷
/
05期
基金:
英国医学研究理事会;
关键词:
biomarkers;
cardiovascular disease;
chronic kidney disease;
coronary disease;
cystatin C;
hydroxymethylglutaryl-CoA reductase inhibitors;
risk assessment;
CHRONIC KIDNEY-DISEASE;
GLOMERULAR-FILTRATION-RATE;
CYSTEINE PROTEASES;
SERUM CREATININE;
DEATH;
EVENTS;
ASSOCIATION;
PRAVASTATIN;
BIOMARKERS;
STRATIFICATION;
D O I:
10.1161/JAHA.121.020745
中图分类号:
R5 [内科学];
学科分类号:
1002 ;
100201 ;
摘要:
BACKGROUND: Elevated plasma cystatin C levels reflect reduced renal function and increased cardiovascular risk. Less is known about whether the increased risk persists long-term or is independent of renal function and other important biomarkers. METHODS AND RESULTS: Cystatin C and other biomarkers were measured at baseline (in 7863 patients) and 1 year later (in 6106 patients) in participants in the LIPID (Long-Term Intervention with Pravastatin in Ischemic Disease) study, who had a previous acute coronary syndrome. Outcomes were ascertained during the study (median follow-up, 6 years) and long-term (median follow-up, 16 years). Glomerular filtration rate (GFR) was estimated using Chronic Kidney Disease Epidemiology Collaboration equations (first GFR-creatinine, then GFR-creatinine-cystatin C). Over 6 years, in fully adjusted multivariable time-to-event models, with respect to the primary end point of coronary heart disease mortality or nonfatal myocardial infarction, for comparison of Quartile 4 versus 1 of baseline cystatin C, the hazard ratio was 1.37 (95% CI, 1.07-1.74; P=0.01), and for major cardiovascular events was 1.47 (95% CI, 1.19-1.82; P<0.001). Over 16 years, the association of baseline cystatin C with coronary heart disease, cardiovascular, and all-cause mortality persisted (each P<0.001) and remained significant after adjustment for estimated GFR-creatinine-cystatin C. Cystatin C also predicted the development of chronic kidney disease for 6 years (odds ratio, 6.61; 95% CI, 4.28-10.20) independently of estimated GFR-creatinine and other risk factors. However, this association was no longer significant after adjustment for estimated GFR-creatinine-cystatin C. CONCLUSIONS: Cystatin C independently predicted major cardiovascular events, development of chronic kidney disease, and cardiovascular and all-cause mortality. Prediction of long-term mortality was independent of improved estimation of GFR. REGISTRATION: URL: https://anzctr.org.au; Unique identifier: ACTRN12616000535471.
引用
收藏
页数:26
相关论文